Variation in antibiotic prescribing and its impact on recovery in patients with acute cough in primary care: prospective study in 13 countries by Butler, Christopher Collett et al.
RESEARCH
Variation in antibiotic prescribing and its impact on recovery
in patients with acute cough in primary care: prospective
study in 13 countries
C C Butler, professor,1 K Hood, director,2 T Verheij, professor,3 P Little, professor,4 H Melbye, professor,5
J Nuttall, senior trial manager,2 M J Kelly, statistician,2 S Mo¨lstad, professor,6 M Godycki-Cwirko, physician,7 J
Almirall, professor,8 A Torres, professor,9 D Gillespie, trainee statistician,2 U Rautakorpi, senior medical
officer,10 S Coenen, postdoctoral fellow,11,12 H Goossens, professor13
ABSTRACT
Objective To describe variation in antibiotic prescribing
for acute cough in contrasting European settings and the
impact on recovery.
Design Cross sectional observational study with
clinicians from 14 primary care research networks in 13
European countries who recorded symptoms on
presentation and management. Patients followed up for
28 days with patient diaries.
Setting Primary care.
Participants Adults with a new or worsening cough or
clinical presentation suggestive of lower respiratory tract
infection.
Main outcome measures Prescribing of antibiotics by
clinicians and total symptom severity scores over time.
Results 3402 patients were recruited (clinicians
completed a case report form for 99% (3368) of
participants and 80% (2714) returned a symptom diary).
Mean symptom severity scores at presentation ranged
from 19 (scale range 0 to 100) in networks based in Spain
and Italy to 38 in the network based in Sweden. Antibiotic
prescribing by networks ranged from 20% to nearly 90%
(53%overall), with wide variation in classes of antibiotics
prescribed. Amoxicillin was overall the most common
antibiotic prescribed, but this ranged from 3% of
antibiotics prescribed in theNorwegian network to 83% in
the English network. While fluoroquinolones were not
prescribed at all in three networks, they were prescribed
for 18% in theMilan network. After adjustment for clinical
presentation and demographics, considerable
differences remained in antibiotic prescribing, ranging
from Norway (odds ratio 0.18, 95% confidence interval
0.11 to 0.30) to Slovakia (11.2, 6.20 to 20.27) compared
with the overall mean (proportion prescribed: 0.53). The
rate of recovery was similar for patients who were and
were not prescribed antibiotics (coefficient −0.01, P<0.01)
once clinical presentation was taken into account.
Conclusions Variation in clinical presentation does not
explain the considerable variation in antibiotic
prescribing for acute cough in Europe. Variation in
antibiotic prescribing is not associated with clinically
important differences in recovery.
Trial registration Clinicaltrials.gov NCT00353951.
INTRODUCTION
Antibiotic resistance is a growing problem worldwide,
with 10% of Streptococcus pneumoniae isolates recorded
as non-susceptible to penicillin in 30 countries in
2007.1 There is wide variation in antibiotic prescribing
for ambulant patients in Europe.2 We do not know if
this variation is explained by differences in presenta-
tion of illness or to which conditions it applies. Acute
cough is one of the most common reasons for consult-
ing. The proportion of European patients consulting in
general practice with lower respiratory tract infection
who are prescribed antibiotics ranges from about 27%
in theNetherlands (for cough and bronchitis) to 75% in
the United Kingdom.34 Trial evidence suggests that
most antibiotic prescriptions do not help these patients
to get better any quicker, although the datasets are
sometimes small and the impact of case mix at presen-
tation is unclear.5-7 Variation in antibiotic prescribing
that does not improve outcomes for patients wastes
resources, undermines self care for similar conditions
in the future, puts patients at unnecessary risk of side
effects, and increases selection of resistant organisms,
and so represents an opportunity for improved care
through greater standardisation. Higher levels of pre-
scribing in certain settings, however, might be
explained by differences in severity of illness and so
variation might not always indicate inappropriate pre-
scribing.We examined variation in antibiotic prescrib-
ing for acute cough in primary care in Europe and its
impact on recovery, controlling for presentation.
METHODS
Networks
The Genomics to combat Resistance against Anti-
biotics in Community-acquired lower respiratory
tract infections in Europe (GRACE) (www.grace-lrti.
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org) Network of Excellence recruited 14 primary care
research networks (based inAntwerp,Helsinki, Roten-
burg, Utrecht, Balatonfured, Milan, Tromso, Lodz,
Bratislava, Barcelona, Mataro, Jonkoping, Cardiff,
Southampton) in 13 countries (Belgium, Finland, Ger-
many, Holland, Hungary, Italy, Norway, Poland, Slo-
vakia, Spain (two networks), Sweden, UK (Wales and
England)).
Recruited networks had access to a minimum of
20 000 patients and had a track record of conducting
research. A national network coordinator and a
national network facilitator took responsibility
for their network’s set up, recruitment, and data
management.
Study materials and procedures
Study materials (protocol, patient diary, and case
report form) and study procedures were developed
with advice from all networks. The coordinators and
facilitators undertook face to face training in study pro-
cedures, including entering data on to the GRACE
online system (GOS), and cascaded training to all par-
ticipating general practitioners.
Study documents required by ethics review commit-
tees and participants (general practitioners and
patients) were translated into local languages.
Back translation by independent translators ensured
accuracy.
Inclusion criteria
Eligible patients were aged 18 and over who were con-
sulting with an illness where an acute or worsened
cough was the main or dominant symptom or had a
clinical presentation that suggested a lower respiratory
tract infection with a duration of up to and including
28 days, were consulting for the first time within this
illness episode, were seen within normal consulting
hours, had not previously participated in the study,
were able to fill out studymaterials, had provided writ-
ten informed consent, and were considered immuno-
competent. These broad inclusion criteria captured a
wide range of patients with community acquired lower
respiratory tract infection.Although almost all patients
with this infection have a cough, the additional eligibil-
ity criterion of clinical presentation suggestive of lower
respiratory tract infection was added to make those
with infection but no cough also eligible.
Recruitment of patients
Participating general practitioners were asked to
recruit consecutive eligible patients in October and
November 2006 and from late January to March
2007. The scheduled two month gap enabled us to
explore the effect of possible temporal variations in
causes of cough during the winter.
Data collection
Clinicians (general practitioners and nurse practi-
tioners) recorded aspects of patients’ history, symp-
toms, comorbidities (diabetes, chronic lung disease,
and cardiovascular disease), clinical findings, andman-
agement, including antibiotic prescription and other
treatments and investigations, on a case report form.
They indicated the presence or absence of 14 symp-
toms (cough, phlegm production, shortness of breath,
wheeze, coryza, fever during this illness, chest pain,
muscle aching, headache, disturbed sleep, feeling gen-
erally unwell, interference with normal activities, con-
fusion/disorientation, and diarrhoea) and then rated
whether each of the symptoms constituted “no pro-
blem,” “mild problem,” “moderate problem,” or a
“severe problem” for the patient. The colour of any
sputumproducedwas recorded as clear, white, yellow,
green, or bloodstained.
Clinicians recorded the patient’s body temperature
with a disposable thermometer (TempaDot, 3M
Health Care) provided in each individual patient
study pack.
Patient reported follow-up
Patients were given a symptomdiary. Theywere asked
to rate 13 symptoms each day until recovery (or for
28 days if symptoms were ongoing) on a seven point
scale from “normal/not affected” to “as bad as it can
be.” Patients rated the same symptoms as the clinicians
apart from confusion/disorientation and diarrhoea. In
addition they were asked to rate the impact of their ill-
ness on their social activities. There were questions
about smoking and course of the illness, including sub-
sequent management and contacts with the health ser-
vice over the next 28 days.
Data management
All data from case report forms and patients’ diaries
were entered via a remote secure data entry portal
onto the GRACE online system that was compliant
with regulatory guidelines. Central and internal mon-
itoring and checking ensured the accuracy of data col-
lection and entry. Patients were telephoned four to
seven days after inclusion to provide them with the
Patients recruited (n=3402)
Eligible patients (n=3398)
Returned case report forms 
(n=3368, 99%)
No missing data
(n=3296, 97%)
Returned diaries 
(n=2714, 80%)
Returned both case report form and diary (n=2690, 79%)
No missing data (n=2560, 75%)
Fig 1 | Patient flow chart
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opportunity to ask questions and discuss any problems
with diary completion.
Sample size
Sample size estimation was based on an estimate of a
probability of 50% for certain events such as treatment
decisions (50% is the most conservative estimate of
probabilities in statistical terms; more common or
more rare events would give more power). This
required a total sample size of 270 per network to
give 95% confidence intervals of 44 to 56 around
detecting that 50% probability within each network.
Though we had no information on the likely level of
clustering of antibiotic prescribingwithin different net-
works, we considered that this conservative approach
to estimation would give enough power for analyses
between networks while accounting for clustering.
Symptom scores
The categories for clinicians to rate the severity of each
symptom as “no problem,” “mild problem,” “moder-
ate problem,” or “severe problem”were scored 1, 2, 3,
and 4, respectively. Scores were calculated for patients
with a minimum of 85% (that is, 12 out of 14 symp-
toms) of their symptoms recorded. This score was
scaled to range between 0 and 100 so that it could be
interpreted as a percentage of maximum symptom
severity.
We calculated patients’ self reported daily symptom
severity scores from the diary data, with scores for 13
symptoms summed and scaled to range between 0 and
100 so that the symptom severity score for a given indi-
vidual on a given day could be interpreted as a percen-
tage of maximum possible symptom severity. This
daily symptom severity score was used as the outcome
variable in patient outcome model.
Analysis
Descriptives—Descriptive statistics by network and
overall were calculated by using means and standard
deviations (SD), medians (interquartile ranges), and
proportions as appropriate. Presented SDs were
inflated for clustering.8
Antibiotic prescribing—Differences in clinical presen-
tation were controlled for by using 13 of the 14 symp-
toms recorded by clinicians (cough was excluded as it
was present in 99.8% of cases), sputum type, tempera-
ture, age, and comorbidities. Antibiotic prescribing by
networks was investigated by using a two level hier-
archical logistic model9 fitted to the data from the
case report formswith patients nestedwithin clinicians.
The dependent variable was whether the clinician pre-
scribed antibiotics or not, with patientswhowere given
a prescription and advised to delay taking the anti-
biotics counted as receiving a prescription. Network
was included as a fixed effect, with all networks being
compared with the overall mean. The impact of smok-
ing status and duration of illness before consulting was
explored in the subset of patients with complete data
(diary responders).
Patients’ recovery—A three level hierarchical ARMA
(1,1) model10 was fitted to the logged daily symptom
scores reported by patients (box). We controlled for
differences in clinical presentation using the same vari-
ables as in the previous model, along with smoking
status and duration of illness before consulting. We
included the impact of differences in antibiotic man-
agement as both a main effect and an interaction with
time (to allow for different recovery rates over time for
those with and without antibiotics).
ARMA model used to assess variation in outcome in
relation to antibiotic prescribing
An ARMA (1,1) model comprises an autoregressive part
and a moving average part and expresses each
observation as a combination of the two:
Xt=εt+Xt−1+εt−1
where Xt is the symptom severity score at time t, εt is the
error term. This allows for each individual’s symptom
severity scores and the related error term to be correlated
with the previous day.
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Fig 2 | Choice of antibiotic by network
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Fig 3 | Unadjusted and adjusted odds ratios for antibiotic prescribing by network (both adjusted
for clustering within clinician). All networks are compared with overall mean
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Statistical analysis software—Descriptive analyses
were performed with SPSS version 14.0 (Chicago,
ILL). All modelling was performed in the R program-
ming language and environment11 using the lme412
and nlme13 packages.
RESULTS
Patients
A total of 3402 patients were recruited by 387 practi-
tioners. Six networks included 270 patients or more,
and all included over 100 (table 1). Four patients
were later found to be ineligible and were excluded
from further analysis. Case report forms were com-
pleted for 3368 (99%) and diary data were obtained
from 2714 (80%) patients. Exclusion of patients with
missing data reduced the case report form dataset to
3296 (97%) and the diary dataset to 2560 (75%)
(fig 1). Those who filled in the diary tended to be
older than those who did not (median age 45
(interquartile range 33-58) v 36 (27-48)). There were
no significant differences in the proportions by sex.
There was some variation in the response rates from
each network, with patients from Eastern European
networks being most likely to return the symptom
diary. Those who did not fill in a diary were no more
or less likely to have been prescribed antibiotics than
the others.
The median age of patients was 45.0 (interquartile
range 35-58), 37% (1228) were men, 98% (3309) were
seen at the office or surgery, 15% (515) had an existing
respiratory condition, 8% (266) had a cardiovascular
related illness, and 4% (138) had diabetes (table 1).
The three most common presenting symptoms, other
than cough (99.7%, 3358), were being generally unwell
(80%, 2698), phlegm production (77%, 2592), and
interference with normal activities (69%, 2335). The
median number of symptoms recorded by a clinician
was eight (6-9). Patients were unwell before the
Table 1 | Countries, networks, general practitioners, practices, and included patients
Site
Patients/
practices/
clinicians Men*
Age
(years)†
Symptom
sever-
ity†‡
Oral temperature*§ Comorbidity*¶
Antibiotic
treatment
Duration
of course
(days)†Low Normal High R H D
Belgium
Antwerp 216/18/26 46.80 (101) 47 (36-60) 31 (21-40) 19.70 (42) 62.90 (134) 17.40 (37) 23.60 (51) 8.30 (18) 3.70 (8) 25.90% (56) 8 (7-8)
Finland
Helsinki 103/2/26 24.30 (25) 45 (34-56) 31 (24-43) 17.50 (18) 76.70 (79) 5.80 (6) 13.60 (14) 2.90 (3) 2.90 (3) 41.70% (43) 9 (7-10)
Germany
Rotenberg 229/16/16 31.00 (71) 40 (29-52) 33 (24-43) 28.50 (65) 65.40 (149) 16.10 (14) 15.30 (35) 7.90 (18) 4.40 (10) 34.50% (79) 7 (6-7)
Holland
Utrecht 200/11/34 44 (88) 57 (42-67) 33 (24-43) 28.50 (57) 68.50 (137) 3.00 (6) 27.00 (54) 15 (30) 7.50 (15) 41.50% (83) 7 (7-7)
Hungary
Balaton-
fured
323/11/11 39.90 (129) 42 (29-53) 26 (17-36) 11.50 (37) 51.10 (165) 37.50 (121) 9.30 (30) 9.00 (29) 4.00 (13) 74.60% (241) 5 (5-7)
Italy
Milan 207/13/12 33.30 (69) 43 (36-58) 19 (12-29) 13.50 (28) 79.20 (164) 7.20 (15) 12.60 (26) 7.20 (15) 2.90 (6) 74.90% (155) 7 (5-7)
Norway
Tromso 203/11/41 36.50 (74) 50 (37-57) 36 (26-43) 21.40 (42) 70.90 (139) 7.70 (15) 22.70 (46) 7.40 (15) 5.40 (11) 30% (203) 10 (7-10)
Poland
Lodz 301/9/21 30.60 (92) 40 (28-55) 36 (26-45) 33.20 (100) 52.50 (158) 14.30 (43) 13.30 (40) 19.90 (60) 2.70 (8) 71.40% (215) 7 (5-7)
Slovakia
Bratislava 299/5/23 33.10 (99) 41 (30-52) 26 (19-36) 2.70 (8) 71.80 (209) 25.40 (74) 13.00 (39) 17.10 (51) 3.30 (10) 87.60% (262) 7 (7-7)
Spain
Barcelona 277/3/25 33.60 (93) 43 (29-59) 19 (14-29) 20.70 (57) 72.40 (199) 6.90 (19) 9.40 (26) 3.60 (10) 3.60 (10) 20.60% (57) 8 (6-8)
Mataro 196/3/21 39.80 (78) 46 (33-64) 19 (13-29) 24.50 (48) 70.90 (139) 4.60 (9) 16.80 (33) 10.20 (20) 5.60 (11) 34.20% (67) 8 (5-8)
Sweden
Jonkoping 300/12/81 36.70 (110) 47.5 (37-61) 38 (29-49) 18.90 (56) 70.70 (210) 10.40 (31) 16.00 (48) 5.30 (16) 3.30 (10) 38% (114) 9 (9-10)
UK
Cardiff 300/5/26 38.30 (115) 45 (34-59) 36 (24-45) 21.30 (64) 74.30 (223) 4.30 (13) 26 (78) 8.00 (24) 5.00 (15) 69.70% (209) 7 (5-7)
Southamp-
ton
214/6/23 39.30 (84) 49 (36-
59.75)
36 (26-43) 10.90 (23) 82.50 (174) 6.60 (14) 20.60 (44) 9.30 (20) 3.70 (8) 62.60% (214) 7 (7-7)
Total 3368/125/
387
36.50
(1228/
3368)
45 (33-58) 31 (19-40) 19.30 (645) 68.20
(2279)
12.50 (417) 15.30
(515)
7.90 (266) 4.10 (138) 52.70%
(1776)
7 (6-7)
*Percentage (number).
†Median (interquartile range).
‡Score scaled to range between 0 and 100.
§Low (<36°c), normal (≥36°c and ≤37.2°c), high (>37.2°c).
¶R=respiratory illness (chronic obstructive pulmonary disease (COPD), asthma, other lung disease); H=heart disease (heart failure, ischaemic heart disease, other heart disease); D=diabetes.
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consultation for a median of five days (3-8). The aver-
age temperature was 36.8ºC (SD 1.59).
Antibiotic prescribing
Antibiotics were prescribed for 53% (1776) of included
patients for a median of seven days (6-7) (table 1).
There were notable differences between networks in
the unadjusted proportion of patients who were pre-
scribed antibiotics. Clinicians from networks based in
Bratislava, Milan, Balatonfured, Lodz, and Cardiff
weremore likely to prescribe antibiotics than the over-
all average.
Amoxicillin accounted for 29%of prescriptions, ran-
ging from 3% in Tromso to 83% in the Southampton
network (fig 2). Macrolides/lincosamides were pre-
scribed for 26%of patients, ranging from4% inUtrecht
to 50%, 45%, and 38% in the Bratislava, Milan, and
Lodz networks, respectively. Co-amoxiclav was pre-
scribed for 15%, though this varied widely, from 0%
in Jonkoping and Tromso to 47% in Barcelona (it was
the most commonly prescribed antibiotic in both Bar-
celona and Mataro (43%)). Tetracyclines were pre-
scribed for 14%. Three networks did not prescribe
tetracyclines at all (Barcelona, Mataro, and Milan),
and they were the first choice in three networks
(Utrecht 72%, Jonkoping 56%, and Helsinki 51%).
Cephalosporins were prescribed for 7% (ranging
from 0% to 13%) and fluoroquinolones for 5%. Fluor-
oquinolones were most commonly prescribed in the
Milan, Mataro, and Balatonfured networks (18%,
16%, and 13%, respectively) and were not prescribed
at all in six networks (Southampton, Barcelona, Lodz,
Jonkoping, Tromso, and Helsinki).
Antibiotic prescribing by networks adjusted for clinical
presentation
Significant variation between networks remained after
adjustment for clinical presentation, with antibiotic
prescribing in 11 networks significantly different
from the overall mean at the 5% level (table 2). Figure
3 shows the unadjusted and adjusted odds ratios for
antibiotic prescribing for all networks.
There were no significant differences between the
two recruitment periods in overall rate of antibiotic
prescribing. The model was also fitted to the subsam-
ple of patients with usable diary data to check the effect
of duration of illness before consultation and smoking
status on prescribing. Both variables were significantly
associated with receiving a prescription for antibiotics,
with a 2% increase in the odds of receiving an antibiotic
for each additional day of illness before consulting
(odds ratio 1.02, 95% confidence interval 1.01 to
1.04) and a 38% increase in the odds for smokers
(1.38, 1.09 to 1.76). Adjustment for these factors, how-
ever, had no effect on the magnitude or significance of
the variation between networks and therefore we have
presented the model with the larger sample.
Patients’ recovery
There was considerable variation between networks in
the rate of recovery after presentation, as shown by the
median symptom trajectory plots (fig 4). The median
time to patients reporting feeling recovered (single
item)was 11 days. Themedian time for patients’ symp-
tom severity scores to drop to 0 was 15 days. Respira-
tory comorbidity was associated with initial higher
symptom severity scores. Those who waited longer
before presenting had higher initial symptom severity
scores.
Significant variation in outcome remained across
networks after adjustment for clinical presentation,
with two of the networks (Balatonfured and Mataro)
reporting differences in patients’ reported symptom
severity at baseline compared with the overall mean,
three networks (Cardiff,Milan, and Jonkoping) report-
ing significantly slower recovery rates, and three net-
works (Mataro, Balatonfured, Antwerp) reporting
Table 2 | Two level logistic regression model* of odds of being prescribed antibiotic in each
network (3296 patients from 384 clinicians). Figures are odds ratios (95% confidence
intervals)
Network OR (95% CI) P value
Antwerp 0.22 (0.12 to 0.38) <0.001
Balatonfured 5.69 (2.88 to 11.26) <0.001
Barcelona 0.29 (0.16 to 0.51) <0.001
Bratislava 11.2 (6.20 to 20.27) <0.001
Cardiff 2.44 (1.42 to 4.19) <0.01
Helsinki 0.58 (0.31 to 1.09) 0.09
Jonkoping 0.25 (0.16 to 0.38) <0.001
Lodz 4.14 (2.4 to 7.16) <0.001
Mataro 0.66 (0.37 to 1.18) 0.16
Milan 6.81 (3.49 to 13.27) <0.001
Rotenberg 0.5 (0.27 to 0.92) 0.03
Southampton 0.84 (0.47 to 1.5) 0.55
Tromso 0.18 (0.11 to 0.30) <0.001
Utrecht 0.5 (0.29 to 0.85) 0.01
*Model controls for clinician rated symptom scores and clinical presentation. Clinician level variance component
was 23.3%, using π2/3 estimator.
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Fig 4 | Unadjusted median symptom severity scores over time
by network
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significantly faster recovery. While there were signifi-
cant differences in the symptom trajectories across the
networks, differences were not large. Almost all the
symptom trajectories converged after a week (fig 5).
Being prescribed antibiotics was associated with a fas-
ter reduction in symptom severity scores, as indicated
by the significant interaction between prescribing anti-
biotics and day. This association, however, was small
(table 3).
The impact of antibiotic prescribing, while statisti-
cally significant, represents a tenth of a single percen-
tage difference in symptom severity score (not
presented), and therefore it is reasonable to consider
it clinically unimportant. Such a small effect is entirely
consistent with a placebo effect.
Hospital admission
Overall, 1.1% (28) of patientswere admitted to hospital
after inclusion. For individual networks this ranged
from none to 4.3% (9).
DISCUSSION
Main findings
In this large prospective international comparative
study of the management of acute cough among adults
in primary care we found considerable variation in the
13 countries studied. Major differences in the decision
whether or not to prescribe an antibiotic in these set-
tings remained, even after we adjusted for clinical pre-
sentation (symptoms, duration of illness, smoking, age,
comorbidity, and temperature). Patients included by
networks based in Bratislava, Milan, Balatonfured,
Lodz, and Cardiff were at least twice as likely to be
prescribed antibiotics than the overall mean. Patients
included by networks based in Tromso, Antwerp, and
Jonkoping were at least four times less likely to be pre-
scribed antibiotics than the overall mean.
We also identified marked differences between net-
works in choice of antibiotic. For example, while
amoxicillin was overall the most common antibiotic
prescribed, this ranged from 3% in the Tromso net-
work to 83% in Southampton.While fluoroquinolones
were prescribed for 5% overall, they were prescribed
for 18% of patients included in the Milan network.
These differences might be attributable to different
guidelines and habits in different countries. This will
be further explored in a parallel qualitative study.
There were two main findings regarding patients’
recovery. Firstly, there were significant differences
between networks in both severity of symptoms on
day one (intercept) and the recovery rate (slope). Dif-
ferences in the recovery rate, however, were small
(fig 5), and patients recovered at a similar rate regard-
less of network. Secondly, whether a patient was pre-
scribed antibiotics or not was statistically associated
with outcome. The magnitude of this association
amounted to a difference of a tenth of a single per
cent in the symptom severity score after seven days,
which is not clinically relevant.
Strengths and limitations
Weprospectively described antibiotic prescribing for a
well definedpopulationof patients in a large number of
countries recruited at the same time. Recruitment was
for two periods over a single winter, and findings by
recruitment period were similar, suggesting local or
temporal variations in cause were unlikely to have
explained the observed differences.
The clinicians who participated (and therefore their
patients) were all affiliated to a research network and so
might not have been representative. In general,
research minded clinicians might be more likely to
practice according to guidelines.14 They would have
been aware of our interest in exploring international
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Table 3 | Estimates for ARMA (1,1) model*: symptom severity scores over time (65 541
observations in 2560 patients from 364 clinicians)
Parameter estimate, P value Interactions with time, P value
Management
Prescribed antibiotics 0.05, 0.26 −0.01, <0.01
Network
Antwerp 0.05, 0.52 -0.01, 0.03
Balatonfured -0.27, <0.001 -0.01, 0.02
Barcelona -0.07, 0.32 0.00, 0.84
Bratislava -0.04, 0.50 -0.00, 0.29
Cardiff 0.09, 0.17 0.01, 0.02
Helsinki 0.03, 0.72 0.00, 0.62
Jonkoping 0.02, 0.78 0.01, <0.001
Lodz -0.05, 0.38 -0.01, 0.07
Mataro 0.28, <0.001 -0.02, <0.001
Milan -0.13, 0.08 0.01, <0.01
Rotenberg 0.02, 0.77 0.00, 0.98
Southampton 0.01, 0.90 0.01, 0.08
Tromso 0.11, 0.14 0.00, 0.42
Utrecht -0.05, 0.52 0.00, 0.88
*Model controls for clinician recorded symptom scores and clinical presentation as well as allowing recovery
trajectory to follow cubic polynomial.
RESEARCH
page 6 of 8 BMJ | ONLINE FIRST | bmj.com
differences in antibiotic prescribing, whichmight have
led to an underestimation of the differences we found.
Bias
As the study spanned 13 European countries, there is
no guarantee that perceptions of health and reporting
of symptoms were consistent. We do not know how
cultural differences influenced our results. We are
exploring these issues in a parallel qualitative study
with patients and clinicians in nine of the networks.
Response bias was not relevant to data from the case
report forms as there was a 99% completion rate. Com-
pletion rates for patients’ diaries ranged from 60% in
the Cardiff network to almost 100% in the Bratislava
network. The overall response rate to the diary was
high (80%). Non-responders might have deteriorated
more than responders, but given similar rates of anti-
biotic prescribing between the two groups and the gen-
erally benign natural clinical course of this condition
this is unlikely. Ascertainment biaswasminimised by a
data collection protocol used by all networks. While
every network followed this protocol, some networks
implemented additional strategies to improve diary
return rates. The impact of different intensities of con-
tact with patients during follow-up is uncertain.
Sample size
This international study was adequately powered to
explore antibiotic prescribing. Only a small number
of patients were admitted to hospital, and there were
no deaths. While this reflects the natural course of
acute cough and the fact that it is managed almost
exclusively in primary care, the low number of such
complications made Europe-wide comparisons on
admission to hospital impossible. For the analysis of
recovery, the combination of the large number of
data points per patient with the large number of
patients made this analysis overpowered with some
significant findings having little or no clinical rele-
vance.
Comparison with previous studies
A study of antibiotic treatment for lower respiratory
tract infection in France, Germany, Italy, Spain, and
the UK over 10 years ago asked general practitioners
to retrospectively describe their management of cases.
Overall, community acquired pneumonia accounted
for 18% of cases, making this a highly unusual sample.
Retrospective data collection carries particular risks of
selection bias and incomplete ascertainment of com-
parable clinical data. Overall, 83% were prescribed
antibiotics.15
In a two country comparison, general practitioners
in Spain and Denmark recorded their management of
respiratory tract infections. Spanish general practi-
tioners prescribed more antibiotics for patients with a
presumed tonsillar and bronchi/lung infection focus.
There was no adjustment for severity and duration of
illness or smoking.16
Implications for practice and research
Some interventions have been shown to successfully
reduce inappropriate antibiotic prescribing in general
practice,17-21 and prescribing fewer antibiotics at the
general practice level is associated with local reduc-
tions in antibiotic resistance.22
We identified marked differences in whether and
what antibiotics are prescribed for acute cough
throughout Europe that remained after adjustment
for clinical presentation based on the clinician’s assess-
ment of symptoms, duration of illness, smoking,
patient’s history (the presence of any comorbidities),
age, and temperature.
We also found that large differences in antibiotic pre-
scribing did not translate to clinically important differ-
ences in patients’ recovery. Therefore management of
acute cough is an issue that is appropriate for standar-
dised international care pathways promoting conser-
vative antibiotic prescribing.
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